Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 13.8% – Time to Buy?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares rose 13.8% during mid-day trading on Friday . The stock traded as high as $2.48 and last traded at $2.48. Approximately 2,742,828 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 2,687,534 shares. The stock had previously closed at $2.18.

Wall Street Analyst Weigh In

TSHA has been the subject of several research reports. JMP Securities reiterated a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Canaccord Genuity Group increased their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Needham & Company LLC restated a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Stock Up 13.3 %

The company’s 50 day simple moving average is $1.97 and its 200-day simple moving average is $2.37. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The firm has a market capitalization of $506.20 million, a PE ratio of 3.92 and a beta of 0.44.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently made changes to their positions in TSHA. Artal Group S.A. increased its stake in Taysha Gene Therapies by 0.7% in the 1st quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock worth $10,583,000 after acquiring an additional 24,444 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Taysha Gene Therapies by 23.7% during the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after purchasing an additional 682,273 shares in the last quarter. State Street Corp increased its position in shares of Taysha Gene Therapies by 4.5% in the third quarter. State Street Corp now owns 3,469,068 shares of the company’s stock worth $6,973,000 after purchasing an additional 150,647 shares during the last quarter. Quantum Private Wealth LLC raised its stake in Taysha Gene Therapies by 5.1% in the third quarter. Quantum Private Wealth LLC now owns 767,616 shares of the company’s stock valued at $1,543,000 after purchasing an additional 37,096 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new stake in Taysha Gene Therapies in the third quarter valued at approximately $931,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.